Publications
Recently published work
2026
Nature Medicine
Post-exposure prophylaxis following Bundibugyo ebolavirus exposure
The monoclonal antibody cocktail MBP134 was administered to adults and children following exposure to Bundibugyo ebolavirus, supporting its further evaluation as post-exposure prophylaxis.
Gaebler C*, Le HN*, Martin L*, Tarnow P*, et al.
*Equal contribution
Read the paper →
https://doi.org/10.1038/s41591-026-04664-4
2026
bioRxiv
Structural characterization of antibodies for synergistic HCMV neutralization
High-resolution structural analysis reveals vulnerable HCMV epitopes and identifies synergistic antibody combinations that achieve enhanced viral neutralization.
A.Ashurov*, J. A.Goldsmith*, A.Ashurov, Z.Yu, M.Koch, N.Classen, L.Schlachter, Z.Saidi, D.Shestopal, K.Hoffmann, H.Hengel, V.Laketa, J. S.McLellan, M.Zehner*, F.Klein* *Equal contribution
View the preprint →
https://doi.org/10.64898/2026.08.22.746424
Selected publications
2026
Nature Medicine
A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir
Uhrig A, Pfäfflin F, Tober-Lau P, Corman VM, Stegemann MS, Tarnow P, Rottstegge M, Heim KM, Bremer F, Cronen T, Lingscheid T, Ngoc Le H, Geus D, Choi MJ, Fischer WA II, Campbell WR, Mehta AK, Addo MM, Mbala-Kingebeni P, Hillus D, Gaebler C, Becker S, Michel J, Nitsche A, Kurth A, Witzenrath M, Best TD, Günther S, Oestereich L, Koch M, Zehner M, Gruell H, Drosten C, Klein F, Charité Ebola Task Force, Kurth F, Sander LE. Nature Medicine (2026), online ahead of print; https://doi.org/10.1038/s41591-026-04663-5
2026
bioRxiv
Identification of a pan-orthoebolavirus-reactive antibody from an rVSV-EBOV vaccinated individual
Tarnow P, Cohen-Dvashi H, Rohde C, Krähling V, Ullrich L, Gieselmann L, Zar Shuker H, Amatya S, Fathi A, Kupke A, Kreer C, BSL-4 Animal Facility Team, Koch M, Addo MM, Becker S, Diskin R, Zehner M*, Klein F*. (*Equal contribution) bioRxiv (2026), preprint; https://doi.org/10.64898/2026.08.28.747769
2025
Journal of Virology
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies
Schultz EP, Ponsness L, Lanchy J-M, Zehner M, Klein F, Ryckman BJ. Journal of Virology 99, e00035-25 (2025); https://doi.org/10.1128/jvi.00035-25
2023
Immunity
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer
Zehner M, Alt M, Ashurov A, Goldsmith JA, Spies R, Weiler N, Lerma J, Gieselmann L, Stöhr D, Gruell H, Schultz EP, Kreer C, Schlachter L, Janicki H, Laib Sampaio K, Stegmann C, Nemetchek MD, Dähling S, Ullrich L, Dittmer U, Witzke O, Koch M, Ryckman BJ, Lotfi R, McLellan JS, Krawczyk A, Sinzger C, Klein F. Immunity 56, 2602–2620.e10 (2023); https://doi.org/10.1016/j.immuni.2023.10.009
2023
Immunity
Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants
Korenkov M*, Zehner M*, Cohen-Dvashi H, Borenstein-Katz A, Kottege L, Janicki H, Vanshylla K, Weber T, Gruell H, Koch M, Diskin R, Kreer C*, Klein F*. (*Equal contribution) Immunity 56, 2803–2815.e6 (2023); https://doi.org/10.1016/j.immuni.2023.11.004
2022
Cell Host & Microbe
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Münn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F. Cell Host & Microbe 30, 1231–1241.e6 (2022); https://doi.org/10.1016/j.chom.2022.07.002
2021
Nature Protocols
Effective high-throughput isolation of fully human antibodies targeting infectious pathogens
Gieselmann L, Kreer C, Ercanoglu MS, Lehnen N, Zehner M, Schommers P, Potthoff J, Gruell H, Klein F. Nature Protocols 16, 3639–3671 (2021); https://doi.org/10.1038/s41596-021-00554-w
2020
Cell
Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
Kreer C*, Zehner M*, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. (*Equal contribution) Cell 182, 843–854.e12 (2020); https://doi.org/10.1016/j.cell.2020.06.044
2020
Cell Host & Microbe
Structural basis for a convergent immune response against Ebola virus
Cohen-Dvashi H, Zehner M, Ehrhardt S, Katz M, Elad N, Klein F, Diskin R.; Cell Host & Microbe 27, 418–427.e4 (2020); https://doi.org/10.1016/j.chom.2020.01.007
2020
Immunity
Antibody teamwork against Ebola virus disease
Zehner M, Klein F. Immunity 52, 217–219 (2020); https://doi.org/10.1016/j.immuni.2020.01.016
2019
Nature Medicine
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Ehrhardt SA*, Zehner M*, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F. (*Equal contribution) Nature Medicine 25, 1589–1600 (2019); https://doi.org/10.1038/s41591-019-0602-4
Recent Talks & conferences
07/2026
Talk at the International Herpesvirus Workshop (Montreal, Canada)
07/2025
Talk at the International Herpesvirus Workshop (Berlin, Germany)
03/2025
Talk at the G/V
(Hamburg, Germany)
07/2024
Talk at the International Herpesvirus Workshop (Portland, USA)
Funding & partnerships behind the work
Meet the organizations and partners supporting our research.
